<DOC>
	<DOCNO>NCT02859727</DOCNO>
	<brief_summary>This study design provide long-term CDZ173 treatment , selective PI3Kδ inhibitor , patient genetically activate PI3Kδ , i.e. , patient APDS/PASLI already participate CDZ173X2201 study . The study open-label design establish long-term safety , tolerability , efficay pharmacokinetics CDZ173 target population .</brief_summary>
	<brief_title>Extension Study Efficacy CDZ173 Patients With APDS/PASLI</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<criteria>Written informed consent must obtain assessment perform . Paients must complete study CCDZ173X2201 , i.e. , EOS visit study CCDZ173X2201 Patients deem Investigator benefit CDZ173 therapy . Patients legal representative ( patient age 18 year ) must able communicate well Investigator , understand comply requirement study . Any medically significant disease condition unrelated APDS/PASLI Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>APDS ; PASLI ; PI3Kdelta ; p110delta-activating mutation cause senescent T cell , lymphadenopathy immunodeficiency ; Activated PI3Kdelta Syndrome ;</keyword>
</DOC>